Our president and CEO, Ted FitzGerald, recently spoke with Jenni Springer, editor of Outsourcing-Pharma, about the COVID-19 immunotherapy trial on which FHI Clinical is partnering with the Infectious Disease Research Institute (IDRI). FHI Clinical is providing full-service CRO capabilities, including project management, medical and clinical monitoring, and data and safety analysis for the trial.
“In this period of crisis, we are incredibly grateful to be able to contribute to understanding of the treatment of COVID-19 through this partnership.”
– Ted FitzGerald, President and CEO, FHI Clinical
In his interview, Ted spoke of the connection FHI Clinical and IDRI made through the Global Health Clinical Consortium (GHCC), an initiative funded by the Bill and Melinda Gates Foundation. Both FHI Clinical and IDRI are long-standing members of GHCC and have teamed together in the past on other studies related to neglected diseases.
FHI Clinical leverages its unique history of working in challenging environments, often in low-income countries, research-naïve sites and outbreak settings. The company has stood up and managed large trials during the 2014-2015 Ebola outbreak in Sierra Leone and the more recent Zika outbreak in Latin America and the Caribbean, among others. One of FHI Clinical’s differentiators is that the company has the experience and expertise to move quickly and nimbly to support trials like this IDRI-led study.
According to Ted, the study is “currently in rapid start-up with the goal of subject enrollment before the U.S. pandemic is expected to decline.”
For more of Ted’s interview, check out the Outsourcing-Pharma article.
Learn more about FHI Clinical’s collaboration with IDRI for this Celularity-funded study.
